title: Role of radiation therapy in clinical hormonally-active pituitary adenomas.
abstract: OBJECTIVE
  The outcome following radiation therapy (RT) of hormonally-active pituitary adenomas was assessed. The purpose of this analysis was to determine the control rate after radiation, identify any prognostic factors and evaluate the late toxicity.
  
  
  METHODS
  From 1972 to 1986, 145 patients received RT for hormonally-active pituitary adenomas. The median age was 39 years (range 15-76), with 81 males and 64 females. There were 52 patients with acromegaly, 64 with prolactinoma, and 29 with Cushing's disease. The median follow-up was 7.3 years. RT was given as primary treatment in 17 patients, after initial surgery in 65 patients, and as part of salvage therapy in 63 patients. The median total dose was 50 Gy (daily fraction: 2 Gy). Tumor control was defined as normalization of basal hormonal level and lack of progression of adenoma assessed by imaging studies. The following factors were analyzed for prognostic significance in tumor control: age, sex, tumor type, direction of tumor extension, radiation dose, and radiation field size.
  
  
  RESULTS
  The 10-year actuarial proportion of patients with persistent elevated hormone level were 61% following RT alone, and 44% with the addition of medical management. The progression-free rate was 96% at 10 years. Of the 20 deaths, three patients died with uncontrolled pituitary adenoma and three died of treatment complications. The actuarial 10-year overall and cause-specific survival rates were 86% and 97%. The actuarial rates of radiation-induced hypopituitarism were 35%, 22% and 22% at 10 years for thyroid, glucocorticoid and gonadal functions, respectively. None of the factors examined were found to be significant predictors of tumor control.
  
  
  CONCLUSIONS
  Post-operative external beam RT is highly effective in preventing recurrence of space-occupying effects of hormonally-active pituitary adenomas. However, long-term biochemical remission is observed only in approximately 40% of patients (at 10 years), with an additional 20% requiring medical therapy. Malignancies of the CNS can develop as an infrequent late event.
authors.affiliation: Department of Radiation Oncology, University of Toronto, Princess Margaret Hospital/Ontario Cancer Institute, Canada.
authors.forename: R W
authors.initials: RW
authors.lastname: Tsang
authors.forename: J D
authors.initials: JD
authors.lastname: Brierley
authors.forename: T
authors.initials: T
authors.lastname: Panzarella
authors.forename: M K
authors.initials: MK
authors.lastname: Gospodarowicz
authors.forename: S B
authors.initials: SB
authors.lastname: Sutcliffe
authors.forename: W J
authors.initials: WJ
authors.lastname: Simpson
mesh_terms: D000172:Acromegaly / Q000532:radiotherapy; D000236:Adenoma / Q000401:mortality / Q000532:radiotherapy*; D000328:Adult; D003131:Combined Modality Therapy; D003480:Cushing Syndrome / Q000532:radiotherapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007018:Hypopituitarism / Q000453:epidemiology / Q000209:etiology; D008297:Male; D010911:Pituitary Neoplasms / Q000401:mortality / Q000532:radiotherapy*; D011379:Prognosis; D015175:Prolactinoma / Q000401:mortality / Q000532:radiotherapy*; D011879:Radiotherapy Dosage; D011882:Radiotherapy, High-Energy; D015996:Survival Rate; D013997:Time Factors; D016896:Treatment Outcome